accountPDL BioPharma Inc. said Monday that Eli Lilly & Co. is licensing its drug candidate teplizumab, an experimental treatment for newly diagnosed type 1 diabetes. PDL said Lilly and its partner MacroGenics are studying teplizumab as a...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to Lilly licenses PDL type 1 diabetes drug candidate
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account